250 related articles for article (PubMed ID: 20517484)
1. The role of rasagiline in the treatment of Parkinson's disease.
Leegwater-Kim J; Bortan E
Clin Interv Aging; 2010 May; 5():149-56. PubMed ID: 20517484
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
Chen JJ; Swope DM; Dashtipour K
Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
[TBL] [Abstract][Full Text] [Related]
3. Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease.
Guay DR
Am J Geriatr Pharmacother; 2006 Dec; 4(4):330-46. PubMed ID: 17296539
[TBL] [Abstract][Full Text] [Related]
4. Rasagiline: A second-generation monoamine oxidase type-B inhibitor for the treatment of Parkinson's disease.
Chen JJ; Ly AV
Am J Health Syst Pharm; 2006 May; 63(10):915-28. PubMed ID: 16675649
[TBL] [Abstract][Full Text] [Related]
5. Rasagiline: a review of its use in the treatment of idiopathic Parkinson's disease.
McCormack PL
CNS Drugs; 2014 Nov; 28(11):1083-97. PubMed ID: 25322951
[TBL] [Abstract][Full Text] [Related]
6. Rasagiline: a review of its use in the treatment of idiopathic Parkinson's disease.
Hoy SM; Keating GM
Drugs; 2012 Mar; 72(5):643-69. PubMed ID: 22439669
[TBL] [Abstract][Full Text] [Related]
7. Rasagiline.
Siddiqui MA; Plosker GL
Drugs Aging; 2005; 22(1):83-91; discussion 93-4. PubMed ID: 15663351
[TBL] [Abstract][Full Text] [Related]
8. Rasagiline: a guide to its use in Parkinson's disease.
Keating GM; Lyseng-Williamson KA; Hoy SM
CNS Drugs; 2012 Sep; 26(9):781-5. PubMed ID: 22834567
[TBL] [Abstract][Full Text] [Related]
9. Rasagiline: a review of its use in the management of Parkinson's disease.
Oldfield V; Keating GM; Perry CM
Drugs; 2007; 67(12):1725-47. PubMed ID: 17683172
[TBL] [Abstract][Full Text] [Related]
10. Rasagiline in Parkinson's disease.
Chahine LM; Stern MB
Int Rev Neurobiol; 2011; 100():151-68. PubMed ID: 21971007
[TBL] [Abstract][Full Text] [Related]
11. Clinical pharmacology of rasagiline: a novel, second-generation propargylamine for the treatment of Parkinson disease.
Chen JJ; Swope DM
J Clin Pharmacol; 2005 Aug; 45(8):878-94. PubMed ID: 16027398
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of adjunctive rasagiline in Japanese Parkinson's disease patients with wearing-off phenomena: A phase 2/3, randomized, double-blind, placebo-controlled, multicenter study.
Hattori N; Takeda A; Takeda S; Nishimura A; Kato M; Mochizuki H; Nagai M; Takahashi R
Parkinsonism Relat Disord; 2018 Aug; 53():21-27. PubMed ID: 29748109
[TBL] [Abstract][Full Text] [Related]
13. Monamine oxidase inhibitors: current and emerging agents for Parkinson disease.
Fernandez HH; Chen JJ
Clin Neuropharmacol; 2007; 30(3):150-68. PubMed ID: 17545750
[TBL] [Abstract][Full Text] [Related]
14. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study.
Parkinson Study Group
Arch Neurol; 2005 Feb; 62(2):241-8. PubMed ID: 15710852
[TBL] [Abstract][Full Text] [Related]
15. Rasagiline meta-analysis: a spotlight on clinical safety and adverse events when treating Parkinson's disease.
Solís-García del Pozo J; Mínguez-Mínguez S; de Groot PW; Jordán J
Expert Opin Drug Saf; 2013 Jul; 12(4):479-86. PubMed ID: 23634791
[TBL] [Abstract][Full Text] [Related]
16. Efficacy, safety and tolerability of rasagiline as adjunctive therapy in elderly patients with Parkinson's disease.
Tolosa E; Stern MB
Eur J Neurol; 2012 Feb; 19(2):258-64. PubMed ID: 21819487
[TBL] [Abstract][Full Text] [Related]
17. Clinical pharmacology tyramine challenge study to determine the selectivity of the monoamine oxidase type B (MAO-B) inhibitor rasagiline.
Goren T; Adar L; Sasson N; Weiss YM
J Clin Pharmacol; 2010 Dec; 50(12):1420-8. PubMed ID: 20445015
[TBL] [Abstract][Full Text] [Related]
18. Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson's disease: a double-blind study as adjunctive therapy to levodopa.
Rabey JM; Sagi I; Huberman M; Melamed E; Korczyn A; Giladi N; Inzelberg R; Djaldetti R; Klein C; Berecz G;
Clin Neuropharmacol; 2000; 23(6):324-30. PubMed ID: 11575866
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic/pharmacodynamic evaluation of rasagiline mesylate for Parkinson's disease.
Müller T
Expert Opin Drug Metab Toxicol; 2014 Oct; 10(10):1423-32. PubMed ID: 25196265
[TBL] [Abstract][Full Text] [Related]
20. Combined rasagiline and antidepressant use in Parkinson disease in the ADAGIO study: effects on nonmotor symptoms and tolerability.
Smith KM; Eyal E; Weintraub D;
JAMA Neurol; 2015 Jan; 72(1):88-95. PubMed ID: 25420207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
